Two-Drug combo aims to wipe out childhood leukemia faster

NCT ID NCT06533748

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving two targeted immunotherapy drugs (inotuzumab and blinatumomab) together at the start of treatment can eliminate leukemia cells more effectively than standard chemotherapy in children and young adults (ages 1-18) with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoma. The goal is to achieve a deep remission with no detectable cancer cells after about one month of therapy. The trial enrolls 128 participants at high risk of relapse and compares results to previous standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia lymphoblastic lymphoma precursor B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Saint Francis Children's Hospital

    RECRUITING

    Tulsa, Oklahoma, 74136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact